Form 4: Glaukos CDO Navratil Boosts Stake with RSU Vesting

Glaukos Corporation's Chief Development Officer, Tomas Navratil, increased his beneficial ownership by over 32,000 shares through the vesting and grant of restricted stock units.

Summary

• Tomas Navratil, Chief Development Officer of Glaukos Corp (GKOS), acquired a total of 32,781 shares of common stock on March 25, 2026, through the vesting and grant of restricted stock units (RSUs).
• This includes 4,622 shares from a March 24, 2022 RSU award, where operational targets were achieved. 50% of these shares will vest and be delivered in March 2026, and the remaining 50% in December 2026.
• An additional 11,693 shares vested from a March 22, 2023 RSU award, based on the achievement of an operational target, with 100% vesting and delivery in March 2026.
• Further, 3,692 shares vested from a March 14, 2024 RSU award, also due to an operational target being met, with 100% vesting and delivery in March 2026.
• Navratil also received a new grant of 12,774 restricted stock units, which will vest over a four-year period, with 25% vesting on each anniversary of the grant date.
• Following these transactions, Navratil's total beneficial ownership stands at 101,238 shares, which includes 57,486 unvested restricted stock units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates the achievement of internal operational targets and strengthens the alignment of a key executive's interests with shareholders through increased equity ownership.

Positives

• The vesting of restricted stock units indicates the achievement of pre-determined operational targets by Glaukos Corporation, reflecting positive company performance.
• Increased insider ownership through equity awards aligns management's interests with those of shareholders.
• The new RSU grant demonstrates continued commitment and incentive for the Chief Development Officer.

Future Outlook

The filing indicates future vesting events for Tomas Navratil's restricted stock units, with portions of the 2022 award expected to vest in December 2026, and the newly granted 12,774 RSUs vesting over a four-year period, 25% on each anniversary of the grant date.

Industry Context

StockSavvy.ai notes that the vesting of performance-based restricted stock units for a Chief Development Officer is a common practice in the medical device and ophthalmology industry, aligning executive incentives with long-term company performance and shareholder value creation. Such equity awards are standard components of executive compensation packages designed to retain key talent and drive strategic objectives.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholders, potentially minor dilution from new share issuance upon vesting.
• Employees: May signal positive company performance and reinforce the effectiveness of performance-based compensation structures.

Next Steps

• Delivery of the remaining 50% of shares from the March 24, 2022 RSU award in December 2026.
• Annual vesting of 25% of the 12,774 newly granted restricted stock units on each anniversary of the grant date over a four-year period.

Key Dates

Keywords

Glaukos Corp, GKOS, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Tomas Navratil, Chief Development Officer, Equity Award, Operational Targets